Takeda Pharmaceutical Co Ltd (TKPHF) stock
TKPHFOTCPharmaceutical PreparationsAlso trades as TAK
$39.00+0.36 (+0.93%)
Close on Oct 19, 2026Market cap $134.41BP/E –Yield –
Takeda Pharmaceutical operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2026 it was ¥6.22B, down 98.2% from the year before. The highest annual figure on record is ¥509.27B in fiscal 2021.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | ¥6.22B | -98.2% |
| FY2025 | Mar 31, 2025 | ¥342.59B | +60.0% |
| FY2024 | Mar 31, 2024 | ¥214.08B | -56.4% |
| FY2023 | Mar 31, 2023 | ¥490.51B | +6.4% |
| FY2022 | Mar 31, 2022 | ¥460.84B | -9.5% |
| FY2021 | Mar 31, 2021 | ¥509.27B | +407.2% |
| FY2020 | Mar 31, 2020 | ¥100.41B | -57.8% |
| FY2019 | Mar 31, 2019 | ¥237.69B | -1.7% |
| FY2018 | Mar 31, 2018 | ¥241.79B | +55.1% |
| FY2017 | Mar 31, 2017 | ¥155.87B | – |